Keywords: vytorin, beats, lipitor, high-risk, patients, data, presented
Vytorin beats Lipitor in high-risk patients
Article | 21 March 2005
Data presented at the American Cardiology Association's annual meeting held in Orlando, USA, revealed that Merck & Co and Schering-Plough's Vytorin ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
